text: Iwgsc-WV-358 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


status: PUBLIC

characteristic: SRA accession

text: Iwgsc-WV-282 - Wheat variety

characteristic: description

text: Triticum aestivum

characteristic: organism

text: Triticum aestivum

characteristic: scientific name

text: The introgression of novel genes from progenitors and related species has been widely employed to improve the agronomic characteristics of hexaploid wheat. This approach, however, has been hampered by the lack of markers that can be used to track introduced chromosome segments. Here, we describe the identification of a large number of single nucleotide polymorphism-based markers that can be used to genotype hexaploid wheat and to identify and track introgression from a variety of sources representing its secondary and tertiary gene pools. We have validated our markers using a high density Axiom® genotyping array. Use of the ultra-high density platform to genotype a range of diploid, tetraploid and hexaploid wheat lines and wheat relatives has confirmed the utility of the markers across a range of species.

characteristic: submission description

characteristic: submission identifier

text: axiom 820K array Triticum aestivum

characteristic: submission title

type: has member

Cereal Genomics

Address: Life Sciences Building,

Paul Wilkinson

FirstName: Paul

LastName: Wilkinson


text: Iwgsc-WV-99 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-113 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Tremie

text: Iwgsc-WV-441 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-459 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-297 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-359 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-339 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-415 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-264 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-223 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-52 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-311 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Solstice

text: Iwgsc-WV-426 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-392 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Exotic

text: Iwgsc-WV-192 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-419 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-207 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-281 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-100 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Bacanora

text: Iwgsc-WV-139 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Rialto

text: Iwgsc-WV-351 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Relay

text: Iwgsc-WV-348 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-101 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-381 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-19 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-461 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-215 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-220 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-338 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Shango

text: Iwgsc-WV-423 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-283 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Optionvar

text: Iwgsc-WV-279 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Glasgow

text: Iwgsc-WV-200 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-328 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Cadenza

text: Iwgsc-WV-153 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-258 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-403 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-362 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Robigus

text: Iwgsc-WV-353 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-327 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Lynx

text: Iwgsc-WV-252 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-81 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-361 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-243 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Biensur

text: Iwgsc-WV-146 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Shamrock

text: Iwgsc-WV-422 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-227 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-69 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-257 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-239 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-304 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-70 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-448 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-44 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-238 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-53 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Humber

text: Iwgsc-WV-210 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-469 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-407 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-363 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-45 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-286 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-462 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-261 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-296 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-322 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Battalion

text: Iwgsc-WV-142 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Avalon

text: Iwgsc-WV-11 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Akteur

text: Iwgsc-WV-5 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-102 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-12 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-124 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-323 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-91 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-288 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-453 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-401 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Gator

text: Iwgsc-WV-198 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-92 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-267 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-295 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-471 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-46 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-375 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-259 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-29 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Revelation

text: Iwgsc-WV-350 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-402 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-103 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-260 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-270 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-454 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Except

text: Iwgsc-WV-191 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-287 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-47 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-271 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-333 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-396 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-434 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-94 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-230 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-429 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-455 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


CresoBulk

text: Iwgsc-WV-163 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Horatio

text: Iwgsc-WV-209 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-93 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-395 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Bermude

text: Iwgsc-WV-145 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-397 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-325 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Alcedo

text: Iwgsc-WV-6 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-269 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Dinosor

text: Iwgsc-WV-176 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-326 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-291 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-332 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Moulin

text: Iwgsc-WV-256 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-48 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-219 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Claire

text: Iwgsc-WV-159 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Cordiale

text: Iwgsc-WV-161 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-95 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-324 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-465 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-39 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-132 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-457 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-463 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-273 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-445 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Soisson

text: Iwgsc-WV-425 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-131 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-303 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Expert

text: Iwgsc-WV-193 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-244 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-125 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-293 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-82 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-182 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Boregar

text: Iwgsc-WV-149 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-272 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-130 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-171 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Delphi

text: Iwgsc-WV-173 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-452 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-168 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-464 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Bobwhite

text: Iwgsc-WV-148 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-40 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-41 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-406 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-68 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-133 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-167 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-4 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Weebil

text: Iwgsc-WV-474 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-266 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-357 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-189 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-83 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-84 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Brompton

text: Iwgsc-WV-150 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-475 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Synthetic

text: Iwgsc-WV-428 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


ChineseSpring

text: Iwgsc-WV-158 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-314 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-265 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Julius

text: Iwgsc-WV-213 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-96 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-382 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Invicta

text: Iwgsc-WV-211 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-439 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-134 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-356 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Garcia

text: Iwgsc-WV-197 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-268 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-458 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-85 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-414 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Apogee

text: Iwgsc-WV-10 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-214 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-123 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-135 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Caphorn

text: Iwgsc-WV-155 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-321 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-86 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-137 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-63 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-218 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-208 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-129 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-42 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-320 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Gallant

text: Iwgsc-WV-196 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-313 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-380 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-405 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-184 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-122 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-87 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-136 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-237 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Diploid

text: Iwgsc-WV-177 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-292 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-372 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-64 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-456 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-433 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Altigo

text: Iwgsc-WV-8 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-373 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-30 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-319 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-104 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-470 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-88 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-400 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-466 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-31 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-242 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-114 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Hobbit

text: Iwgsc-WV-206 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-65 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-404 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-408 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-77 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-90 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Rocky

text: Iwgsc-WV-354 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-97 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-290 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-365 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-89 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-43 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-32 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-383 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Beluga

text: Iwgsc-WV-143 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-188 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-438 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Fabian

text: Iwgsc-WV-194 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-73 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-186 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-72 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Skyfall

text: Iwgsc-WV-424 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-71 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-467 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-344 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Target

text: Iwgsc-WV-435 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-187 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-451 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Duxford

text: Iwgsc-WV-178 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-33 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-289 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: Iwgsc-WV-329 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Viscount

text: Iwgsc-WV-446 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


Tuerkis

text: Iwgsc-WV-443 - Wheat variety

text: Triticum aestivum

text: Triticum aestivum

text: axiom 820K array Triticum aestivum


text: giant hogweed

characteristic: common name

unit: YYYY-MM-DD

characteristic: date received

text: Apiaceae

characteristic: family

text: individual

characteristic: material

text: Apiales

characteristic: order

text: Heracleum mantegazzianum

text: Daniel Mead

characteristic: provider

text: The project's primary goal is to sequence 25 novel genomes representing UK biodiversity, as part of the Wellcome Sanger Institute's wider 25th Anniversary celebrations. This project will be a pathfinder for future long-read sequencing projects to demonstrate the Institute’s capabilities and will provide reference genomes for the global scientific community.

text: 25 Genomes Project

Wellcome Sanger Institute

Address: Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK

Daniel Mead

FirstName: Daniel

LastName: Mead

Role: Project Coordinator


text: New Zealand flatworm

text: Geoplanidae

text: individual

text: Tricladida

text: Arthurdendyus triangulatus

text: René van der Wal

text: 25 Genomes Project


text: prickly Florida blackberry

text: Rosaceae

text: individual

text: Rosales

text: Rubus argutus

text: Hamid Ashrafi

text: 25 Genomes Project


unit: year

characteristic: animal age at collection

text: tongue (olfactory) from an adult male texel x blackface sheep, OAR_RI_AM2

text: adult

characteristic: developmental stage

text: fed

characteristic: fasted status

text: normal

characteristic: health status at collection

text: specimen from organism

text: Ovis aries

text: tonsil

characteristic: organism part

text: tongue

text: FAANG

characteristic: project

characteristic: specimen collection date

characteristic: specimen collection protocol

text: The Roslin Institute Sheep Gene Expression Atlas Project

text: Roslin Sheep Atlas

type: derived from

BBSRC

Role: funder

Address: Polaris House, North Star Avenue, Swindon, Wiltshire, SN2 1UH

EMBL-EBI

Role: curator

Address: Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, United Kingdom

Name: The Roslin Institute and Royal Dick School of Veterinary Studies

Role: biomaterial provider

Address: Easter Bush Campus, Edinburgh, Midlothian, EH25 9RG

Role: institution

Alan Archibald

FirstName: Alan

LastName: Archibald

MidInitials: L

Role: Investigator

Bruce Whitelaw

FirstName: Bruce

LastName: Whitelaw

MidInitials: C

David Hume

FirstName: David

LastName: Hume

MidInitials: A

Emily Clark

FirstName: Emily

LastName: Clark

Role: experiment performer

Role: submitter

Kim Summers

FirstName: Kim

LastName: Summers

MidInitials: M

Mary McCulloch

FirstName: Mary

LastName: McCulloch

MidInitials: B

Mick Watson

FirstName: Mick

LastName: Watson

Stephen Bush

FirstName: Stephen

LastName: Bush

MidInitials: J

Role: data analyst


BTA_RI_MALE 2_BMDM_7hrsLPS

characteristic: SRA accession

text: inflammatory macrophage

characteristic: cell type

text: bone marrow derived macrophage (+LPS, 7hrs) from a 2 day old, Holestein Friesian, Scotland

characteristic: description

text: cell specimen

text: Bos taurus

characteristic: organism

text: FAANG

characteristic: purification protocol

text: RNA sequencing of cattle (Bos taurus) bone marrow derived macrophages (BMDMs), both unstimulated and 7 hours after stimulation with lipopolysaccharide (LPS)

characteristic: submission description

David Hume

MidInitials: DA

Role: investigator

Lucas Lefevre

FirstName: Lucas

LastName: Lefevre

Rachel Young

FirstName: Rachel

LastName: Young

MidInitials: R

MidInitials: S


BTA_RI_MALE 4_BMDM

text: bone marrow macrophage

text: bone marrow derived macrophage from a 1 day old, Holestein Friesian, Scotland

text: cell specimen

characteristic: material

text: Bos taurus

text: FAANG

characteristic: submission identifier

characteristic: submission title


BTA_RI_MALE 1_BMDM_7hrsLPS

text: inflammatory macrophage

text: bone marrow derived macrophage (+LPS, 7hrs) from adult male, 8 months old, Holestein Friesian, Scotland

text: cell specimen

text: Bos taurus

text: FAANG


BTA_RI_MALE 4_BMDM_7hrsLPS

text: inflammatory macrophage

text: bone marrow derived macrophage (+LPS, 7hrs) from a 1 day old, Holestein Friesian, Scotland

text: cell specimen

text: Bos taurus

text: FAANG


BTA_RI_MALE 3_BMDM

text: bone marrow macrophage

text: bone marrow derived macrophage from an adult male, 15 months old, Holestein Friesian, Scotland

text: cell specimen

text: Bos taurus

text: FAANG


BTA_RI_MALE 1_BMDM

text: bone marrow macrophage

text: bone marrow derived macrophage from an adult male, 8 months old, Holestein Friesian, Scotland

text: cell specimen

text: Bos taurus

text: FAANG


BTA_RI_MALE 3_BMDM_7hrsLPS

text: inflammatory macrophage

text: bone marrow derived macrophage (+LPS, 7hrs) from adult male, 15 months old, Holestein Friesian, Scotland

text: cell specimen

text: Bos taurus

text: FAANG


BTA_RI_MALE 2_BMDM

text: bone marrow macrophage

text: bone marrow derived macrophage from a 2 day old, Holestein Friesian, Scotland

text: cell specimen

text: Bos taurus

text: FAANG


unit: day

characteristic: animal age at collection

text: ileum from a male 8 week old texel x blackface lamb, OAR_RI_L8

text: juvenile days 45-89

text: fed

text: normal

text: specimen from organism

text: Ovis aries

text: ileum

text: FAANG

text: Roslin Sheep Atlas


text: Human

characteristic: common name

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003877-T01

text: Homo sapiens

text: Homo sapiens

characteristic: scientific name

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway

Department of Medicine

Address: 300 E 66th St Room 819, New York, NY 10004, USA

Pedram Razavi

FirstName: Pedram

LastName: Razavi


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004052-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009731-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007009-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005818-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006660-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007566-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009859-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013118-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004850-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004908-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000175-T03

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005426-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001505-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004090-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001452-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003779-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009740-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012005-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006309-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003431-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014034-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009636-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011415-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014276-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009821-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015794-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010245-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009122-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003224-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006622-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001419-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013586-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005314-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015355-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014091-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001184-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003166-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000216-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000597-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008795-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000786-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005265-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014040-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006910-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012148-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004835-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003493-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008574-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013585-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006741-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008712-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013117-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005469-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001290-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006963-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001395-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006558-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005152-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006315-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002640-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015828-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013562-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001932-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003376-T02

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014320-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001874-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011449-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015496-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010043-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010800-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001979-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008481-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005932-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000595-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000864-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005242-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0016277-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000422-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007129-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006723-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000276-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009931-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004183-T03

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012318-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010709-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004654-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012572-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0016239-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004896-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008204-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010201-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013715-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015428-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004289-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014130-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008471-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011247-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013990-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000490-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007888-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001672-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010939-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011280-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008400-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015561-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015742-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003866-T03

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004974-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005688-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011373-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003888-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008679-T03

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004728-T02

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015689-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014267-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009688-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000102-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004295-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003216-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002096-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004580-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007902-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006310-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002115-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011392-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014970-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003634-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012186-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010077-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004196-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012560-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004392-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002176-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009725-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012858-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012534-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006447-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000584-T03

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013617-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004388-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011365-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002545-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003893-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006563-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015437-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002366-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015598-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007231-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001149-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000278-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012176-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015948-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009026-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015784-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014251-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015499-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009966-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012372-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007741-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008448-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013105-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005904-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004375-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001166-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003652-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008179-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002652-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011040-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001934-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006051-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012214-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0016135-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013887-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0016003-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012632-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008945-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015930-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005972-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010919-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009738-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006601-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012836-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002131-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013707-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011386-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001212-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005009-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008398-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013265-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004646-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003787-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004178-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004309-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007564-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014903-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002828-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011250-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011592-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011400-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004665-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003223-T03

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004195-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002942-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002244-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015565-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004216-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013269-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003606-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004434-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015743-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015229-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001888-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014622-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003265-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008346-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013622-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010427-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009630-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010933-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005429-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006169-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011305-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014092-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008833-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015099-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014384-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010508-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015063-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014703-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010922-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008714-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013108-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012863-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013172-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006842-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014627-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010684-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013507-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001889-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004316-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015473-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0011442-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010488-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004768-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013059-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000532-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015831-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001608-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007671-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006286-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003933-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005781-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010925-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010754-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007496-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013734-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008666-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010930-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010431-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013577-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012996-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010058-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003147-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001508-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015207-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003591-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013219-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013895-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014298-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004450-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000435-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006227-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014483-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014951-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010942-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014431-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013915-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002682-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003950-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004758-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006162-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002975-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004264-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009021-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006631-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013299-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013584-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005423-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007396-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003958-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012243-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013491-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006847-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002531-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014907-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0001417-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010244-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000620-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010296-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013908-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014406-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0009155-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006568-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002139-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0006074-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003025-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012288-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0002399-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0003005-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005360-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008049-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0005131-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0014067-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010655-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004748-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015476-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0013925-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004165-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0012153-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008082-T01

text: Homo sapiens

text: Homo sapiens

text: To determine whether genomic alterations in pre-treatment tumor samples might be associated with resistance to CDK4/6 inhibitors (CDK4/6i) in patients with metastatic breast cancer, we subjected 348 ER+/HER2- breast cancer tumor samples to targeted sequencing using MSK-IMPACT assay. A total of 15 tumors did not harbor somatic non-synonymous mutations and were not included in this submission. All the tumors were procured prior to initiation of any of the three clinically efficacious CDK4/6i (palbociclib, ribociclib or abemaciclib; although the majority of patients received palbociclib in this cohort). We then performed an analysis to determine the association between somatic mutations and copy number alterations inferred to be biologically and therapeutically relevant with progression-free survival on CDK4/6i.


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010979-T01

text: Homo sapiens

text: Homo sapiens

text: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010917-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004999-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0015924-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008211-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008846-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0004523-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0000871-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007327-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0007577-T01

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0008024-T02

text: Homo sapiens

text: Homo sapiens


text: Human

text: Breast Cancer Tumor Sequenced Samaple, case: P-0010843-T01

text: Homo sapiens

text: Homo sapiens